Published

Latent Class Analysis of Changes in Substance Use and Depressive Symptoms following Naturalistic Psilocybin Use: Results from a Prospective Longitudinal Survey

No abstract availability was recorded for this entry.

Open source BibTeX RIS

Bibliographic context

Journal: Drug and Alcohol Dependence
Date: 2025-02-01
Source: OpenAlex
DOI: 10.1016/j.drugalcdep.2024.112184
PubMed: Unavailable

Authors

Jérémie Richard Sandeep M. Nayak Nathan D. Sepeda Albert Garcia-Romeu

Watch author

Derived topics and classifications

psilocybin Depression Anxiety Addiction Observational Study Observational Study

Citation graph

0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

Indexed papers citing this DOI

Latent Class Analysis of Changes in Substance Use and Depressive Symptoms following Naturalistic Psilocybin Use: Results from a Prospective Longitudinal Survey2025-02-01

Related papers

A Randomized, Double-Blind, Single Ascending Dose Study to Identify a Safe and Non-Psychedelic Dose of PsilocybinClinicalTrials.gov · 2026-07-17 PSilocybin Microdose for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site Phase 3 Double-blind, Placebo-controlled, Parallel-arm Clinical TrialClinicalTrials.gov · 2026-07-10 The Therapeutic Potential of Psilocybin in Anorexia Nervosa in Young AdultsClinicalTrials.gov · 2026-08-14 Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin (NECTAR) in Aging and Alzheimer's DiseaseClinicalTrials.gov · 2026-08-07 Single Dose Psilocybin for a Post-surgical Trauma Inpatient Population for Pain, Mood, and Opioid Use DisorderClinicalTrials.gov · 2026-08-06 PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site, Open-label, Single Arm Phase I/II Proof-of-concept, Dose-finding, and Feasibility Clinical TrialClinicalTrials.gov · 2026-07-10 Acute Effects of MDMA Co-administration on the Response to Psilocybin in Healthy SubjectsClinicalTrials.gov · 2026-06-25 A Phase 2a Study of Group Retreat Psilocybin Therapy for Cancer-Related Anxiety and DepressionClinicalTrials.gov · 2026-07-31